C8 Dihydroceramide

C8 Dihydroceramide

• CAS Number: 145774-33-0
• UNSPSC Description: C8 Dihydroceramide is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro[1][2][3][4].
• Target Antigen: PKC
• Type: Reference compound
• Related Pathways: Epigenetics;TGF-beta/Smad
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/c8-dihydroceramide.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(N[C@H]([C@@H](CCCCCCCCCCCCCCC)O)CO)CCCCCCC
• Molecular Weight: 427.70
• References & Citations: [1]Rebeca López-Marure , et al. Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem Biophys Res Commun. 2002 May 10;293(3):1028-36.|[2]Yuli C. Chang, et al. Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells. Int J Mol Sci. 2018 Oct; 19(10): 3010.|[3]H W Huang, et al. Ceramides modulate protein kinase C activity and perturb the structure of Phosphatidylcholine/Phosphatidylserine bilayers. Biophys J. 1999 Sep; 77(3): 1489-1497.|[4]Lan Weiss, et al. Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy. Hum Mol Genet. 2021 Jan 7;ddaa248.|[5]Rebeca López-Marure, et al. Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem Biophys Res Commun. 2002 May 10;293(3):1028-36.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported